ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD, engl.

Transparency

ESC guideline outside the German AWMF system (https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Diabetes-Pre-Diabetes-and-Cardiovascular-Diseases-developed-with-the-EASD ). Of the 24 authors, only 2 (8%) stated that they do not have conflicts of interest. The statement is limited to the years 2017/18. Twenty-two authors (92%), including the lead authors, declared conflicts of interest (https://www.escardio.org/static_file/Escardio/Guidelines/DOI/DOI_Summary_2019_DIABETES.pdf).

Composition of the Guideline Working Group

Of the 22 authors with conflicts of interest, 15 (63 percent of all authors) declared a direct conflict of interest with the anti-diabetic drug industry. Seven of the authors (29 percent of all authors) have a conflict of interest involving products evaluated in the guideline.

Independence of the Coordinators/Chairs/Lead AuthorsUnabhängigkeit der Vorsitzenden/federführenden Autoren

The two lead authors representing the two scientific medical societies issuing the guideline declare conflicts of interest.

Abstention from Voting

As in other ESC guidelines, no detailed information is provided regarding the process of drafting the guideline. Consequently, we do not know whether authors with conflicts of interest participated in any voting relevant to their conflicts.

External Review of the Guideline

Ninety-seven reviewers are listed by name. The review process was not public and is not documented in detail. Seventy-seven of the reviewers (79 percent) declare conflicts of interest. Twenty of the reviewers (21 percent) stated that they had no conflicts of interest, but only for the year 2018.

Bonus Points